The Patent of ATC will expire in December 2013, assuming no extension under US's HW Act (Wilson HTM Note on AVX, 20 Feb 2008).
IMO, this is one of the reasons why AVX could not secure the partnership with big pharma yet since it will be of only 1 or 2 years left if ATC is lucky enough to be approved by Year 2012 as the 2nd-line for HIV treatment.
